Written question asked by Ruth Edwards (Conservative) on Friday, 15 October 2021, in the House of Commons. It was due for an answer on Tuesday, 19 October 2021. It was answered by Edward Argar (Conservative) on Thursday, 28 October 2021 on behalf of the Department of Health and Social Care.
Fampridine
- Question
-
To ask the Secretary of State for Health and Social Care, what recent assessment has made of the potential merits of using fampridine for the treatment of multiple sclerosis.
- Answer
-
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources.
NICE was unable to recommend fampridine as an effective use of resources in its clinical guideline on managing multiple sclerosis. However, NICE is now updating this guideline, which will include reviewing the recommendation on fampridine. NICE expects to publish its draft guidance on the management of multiple sclerosis for consultation in December this year, with final guidance expected on 1 June 2022.
Secondary information
- Type
- Written question
- Reference
- 56497
- Session
- 2021-22
- Subjects
- Fampridine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2021-10-28 15:08:15 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56497
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56497
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/56497